ERBB2 and breast cancer: Growing evidence has suggested that the HER2 status of breast cancer patients may change over the course of therapy and those patients with HER2-overexpressing primary tumors may not benefit from anti-HER2 therapy if they lose HER2 expression in their metastatic sites [26, 27].